Biomedical Engineering Reference
In-Depth Information
70. Simpson AJ, Wallace WA, Marsden ME, et al. Adenoviral augmentation of
elafin protects the lung against acute injury mediated by activated neutrophils
and bacterial infection. J Immunol 2001; 167:1778-1786.
71. Vachon E, Bourbonnais Y, Bingle CD, Rowe SJ, Janelle MF, Tremblay GM.
Anti-inflammatory effect of pre-elafin in lipopolysaccharide-induced acute
lung inflammation. Biol Chem 2002; 383:1249-1256.
72. Nagase H, Brew K. Engineering of tissue inhibitor of metalloproteinases
mutants as potential therapeutics. Arthritis Res 2002; 4(suppl 3):S51-S61.
73. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological
actions and therapeutic opportunities. J Cell Sci 2002; 115:3719-3727.
74. Williamson RA, Marston FA, Angal S, et al. Disulphide bond assignment in
human tissue inhibitor of metalloproteinases (TIMP). Biochem J 1990; 268:
267-274.
75. Will H, Atkinson SJ, Butler GS, Smith B, Murphy G. The soluble catalytic
domain of membrane type 1 matrix metalloproteinase cleaves the propeptide
of progelatinase A and initiates autoproteolytic activation. Regulation by
TIMP-2 and TIMP-3. J Biol Chem 1996; 271:17119-17123.
76. Yu WH, Yu S, Meng Q, Brew K, Woessner JF Jr. TIMP-3 binds to sulfated
glycosaminoglycans of the extracellular matrix. J Biol Chem 2000; 275:
31226-31232.
77. Amour A, Knight CG, Webster A, et al. The in vitro activity of ADAM-10 is
inhibited by TIMP-1 and TIMP-3. FEBS Lett 2000; 473:275-279.
78. Amour A, Slocombe PM, Webster A, et al. TNF-alpha converting enzyme
(TACE) is inhibited by TIMP-3. FEBS Lett 1998; 435:39-44.
79. Gomis-Ruth FX, Maskos K, Betz M, et al. Mechanism of inhibition of the
human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997;
389:77-81.
80. Fernandez-Catalan C, Bode W, Huber R, et al. Crystal structure of the
complex formed by the membrane type 1-matrix metalloproteinase with the
tissue
inhibitor of metalloproteinases-2,
the
soluble progelatinase A
receptor. EMBO J 1998; 17:5238-5248.
81. Huang W, Meng Q, Suzuki K, Nagase H, Brew K. Mutational study of the
amino-terminal domain of human tissue inhibitor of metalloproteinases 1
(TIMP-1) locates an inhibitory region for matrix metalloproteinases. J Biol
Chem 1997; 272:22086-22091.
82. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for
macrophage elastase for cigarette smoke-induced emphysema in mice. Science
1997; 277:2002-2004.
83. Leco KJ, Waterhouse P, Sanchez OH, et al. Spontaneous air space enlarge-
ment in the lungs of mice lacking tissue inhibitor of metalloproteinases-3
(TIMP-3). J Clin Invest 2001; 108:817-829.
84. Lim S, Roche N, Oliver BG, Mattos W, Barnes PJ, Fan Chung K. Balance of
matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveo-
lar macrophages in cigarette smokers. Regulation by interleukin-10. Am J
Respir Crit Care Med 2000; 162:1355-1360.
85. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix
metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar
